ClinicalTrials.gg
RecruitingNCT05865002Updated Apr 17, 2026

A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)

A Phase 1 interventional study of AUR107 in Relapsed Malignant Solid Neoplasm, sponsored by Aurigene Discovery Technologies Limited. Recruiting at 37 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Aurigene Discovery Technologies Limited (part of Dr. Reddy's Laboratories Limited) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 136 studies in Carcinoma, Non-Small-Cell Lung with a site in India — 25 open to participants now, 54 under way, 46 of them phase 3. Carcinoma, Non-Small-Cell Lung · India.

Planned enrollment
115th of 124
50 · median 430
Started
2023
with 4 others
Phase 1
3 of 136
1 open now
Primary completion
2027-01
later than 26 of 53 live
Registered
107th of 136
by date

Among the 136 studies in Carcinoma, Non-Small-Cell Lung with a site in India, this one is the 115th largest by planned enrollment of the 124 interventional ones that give a count, is one of 5 that started in 2023, is one of 3 in phase 1, reaches primary completion later than 26 of the 53 other live ones, and was the 107th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

25 of the 136 studies in Carcinoma, Non-Small-Cell Lung with a site in India are open now. Recruiting first, the newest first:

19 more — sign in →

All 25 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies in Carcinoma, Non-Small-Cell Lung with a site in India, or all of them as a file.
02

Study summary

An open-label, first-in-human, Phase 1 study in adult patients with relapsed advanced malignancies will be done to assess AUR107 safety, tolerability, pharmacokinetics, pharmacodynamics, and optimal biological dose.

Read the detailed description

This is a Phase I, Open Label, Dose-Escalation, First-in-Human study in adult patients with select relapsed advanced malignancies. The safety and tolerability of oral AUR107 will be evaluated in patients with selected advanced solid tumors (Non-small cell lung cancer, Gastric cancer, Urothelial cancer, Kidney cancer, Colon cancer, and Esophageal cancer) who do not have any available curative or life-prolonging treatment options and have exhausted all effective locally available therapies. The traditional 3+3 design for dose escalation will be used to evaluate the safety, pharmacokinetics/pharmacodynamics, and determine the Optimal Biological Dose of AUR107 as a single agent. The Optimal Biological Dose will be selected using a totality of safety, PK, and PD data.

03

Conditions studied

  • Relapsed Malignant Solid Neoplasm

Keywords

  • Relapse malignant neoplasm
  • Non small cell lung cancer
  • Gastric cancer
  • Colon cancer
  • Esophageal cancer
  • Kidney cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females ≥ 18 years of age.
  2. (ECOG) Performance status of 0 or 1.
  3. Acceptable bone marrow and organ function at screening as described below:

    1. ≥ 1500/μL (without WBC growth factor support)
    2. count ≥ 100,000/μL without transfusion support
    3. ≥ 9 g/dL (Transfusion is allowed to achieve this Hb)
    4. Total ≤ 1.5 x ; (Patients with known Gilbert's syndrome are allowed with a Total Bilirubin ≤ 2.5 x ULN)
    5. (SGOT) ≤ 3 x ULN (≤ 5 × ULN if known liver )
    6. ALT (SGPT) ≤ 3 x ULN (≤ 5 × ULN if known liver metastases)
    7. (CrCl) ≥ 60 mL/min (either measured or estimated by the Cockcroft-Gault formula).
  4. Ability to swallow and retain oral medications.
  5. Histopathological diagnosis of a solid tumor. Note: The solid tumors must be in Stage IV at screening.
  6. Evidence of per , v1.1 for solid tumors.
  7. Standard curative measures do not exist, and the patient must have exhausted all effective therapies available locally.

Notes:

7a. At a minimum, solid tumor patients must have received at least two in the metastatic incurable settings (these two lines must be in the metastatic setting and not in the earlier stage of cancer).

7b. Any cancer patient with access to any effective therapy must not be enrolled

Exclusion criteria

Exclusion Criteria:

  1. Systemic anti-cancer therapy, such as chemotherapy, biological therapy, or immunomodulatory drug therapy, received within the past 28 days or 5 half-lives, whichever is longer, from Cycle 1 Day 1 of the study.

    Note: Concomitant use of low-dose prednisone (up to 10 mg/day) or medroxyprogesterone is allowed.

    Note: Patients with CRPC (castrate-resistant prostate cancer) should continue to receive ongoing medical castration with LHRH analogs, and such patients are allowed.

  2. Presence of acute or chronic toxicity resulting from prior anticancer treatment, with the exception of alopecia or nail changes, that has not resolved to Grade ≤ 1, as determined by v 5.0.
  3. Definitive Radiotherapy within the last 21 days of Cycle 1 Day 1 (limited field palliative radiation is allowed and no restrictions during the screening period or during the trial)

    • Use of any agent within 28 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  4. Use of drugs which are moderate / strong inducers and/or drugs which are predominantly metabolized by CYP3A4 within 1week or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.

    • Note: This class of drugs are also prohibited during DLT evaluation period and must be either avoided or used with caution beyond DLT evaluation period.
  5. Known symptomatic or untreated or recently treated (≤ 6 months of screening) central nervous system (CNS) . Patients with previously treated (> 6 months of screening) and are now stable and asymptomatic, from CNS perspective, are allowed.
  6. Major surgery ≤ 28 days from Cycle 1 Day 1 (major surgery is defined as a procedure requiring general anesthesia).
  7. Patients with leukemia, myelodysplastic syndrome, multiple myeloma, or lymphoma.
  8. Active infection requiring systemic therapy. Note: Prophylactic use of antibiotics is allowed. Any infection detected during the screening period which is resolved adequately according to investigator before the Cycle 1 Day 1, is allowed.
  9. Known to be (HIV) positive or have an acquired immunodeficiency syndrome-related illness.
  10. Known active or chronic (HBsAg +ve) or infection (HCV antibody +ve).
  11. The patient who is expected to require any other form of antineoplastic therapy or targeted therapy while on study.
  12. Uncontrolled congestive heart failure ( [NYHA] Class 2-4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, or , or pulmonary embolism within 3 months prior to Cycle 1 Day 1.
  13. Ongoing cardiac dysrhythmias requiring treatment of any grade or treatment of cardiac dysrhythmias in the past 3 months, before Cycle 1 Day 1.
  14. (Bazzett) interval >460 ms on at screening and/or at Cycle 1 Day 1 pre-dose.
  15. Uncontrolled intercurrent illness including, but not limited to, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, active peptic ulcer disease or significant gastritis, active bleeding diatheses, presence of any major medical illness (e.g., renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or psychiatric illness/social situations or laboratory / ECG abnormalities at screening, any or a combination of illnesses, which, in the opinion of the PI, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study.
  16. Current swab-positive or suspected (under investigation) Covid-19 infection or fever and other signs or symptoms suggestive of Covid-19 infection with recent contact of the person(s) with confirmed Covid-19 infection, at screening or Day 1 of Cycle 1.
  17. Positive pregnancy test for women of (WOCBP) at the screening or enrolment visit.
  18. Lactating women or WOCBP who are neither surgically sterilized nor willing to use reliable methods. (hormonal contraceptive, IUD, or any double combination of the male or female condom, spermicidal gel, diaphragm, sponge, cervical cap).
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    AUR107, 5mg to 200mg

    Currently, planned dose levels are 5 mg QD, 10 mg QD, 20 mg QD, 40 mg QD, 60 mg QD, 90 mg QD, 135 mg QD, and 200 mg QD

    Drug: AUR107

Interventions

  • DrugAUR107

    Once daily

06

What researchers measure

Primary outcomes

  1. First cycle Dose Limiting Toxicities (DLT)

    Assess dose limiliting toxicities of AUR107

    Time frame: 28 days

  2. Safety of AUR107 as measured by the number of participants with treatment-related adverse events (AE) graded according to NCI CTCAE version 5.0

    The assessment of safety was based on the frequency of deaths, AEs, SAEs, AEs leading to discontinuation of study drug, and abnormalities in specific clinical laboratory assessments. AEs and laboratory values will be graded for severity according to the NCI CTCAE version 5.0.

    Time frame: 28 days

  3. Optimal Biological Dose

    Determine optimal Biological dose

    Time frame: 28 days

  4. Pharmacokinetics: Maximum concentration (Cmax)

    Maximum concentration of AUR107

    Time frame: Day 1 and Day 15

  5. Pharmacokinetics: Time to Maximum concentration (Tmax)

    Tmax in hours

    Time frame: Day 1 and Day 15

  6. Pharmacokinetics: Area under the curve (AUC)

    Area under the curve (AUC) of AUR 107 in h\* mcg/mL

    Time frame: Day 1 and Day 15

  7. Pharmacokinetics: Mean Residence Time (MRT)

    Average time the drugs stays in the body

    Time frame: Day 1 and Day 15

  8. Pharmacokinetics: Terminal elimination half-life

    Terminal elimination half-life of AUR 107 in hours

    Time frame: Day 1 and Day 15

  9. Maximum concentration (Cmax) administered under fasting/fed condition

    Compare in fast and fed conditions

    Time frame: Day 8 and Day 9

  10. Time to Maximum concentration (Tmax) administered under fasting/fed condition

    Compare Tmax in fast and fed conditions

    Time frame: Day 8 and Day 9

  11. Area under curve (AUC) administered under fasting/fed condition

    Compare AUC in fast and fed conditions

    Time frame: Day 8 and Day 9

Other outcomes

  1. Exploratory endpoint: Identification of gene expression profiles

    Pharmacodynamic marker: Gene Expression profile as assessed by RNA analysis

    Time frame: Day 1, Day 2, and Day 15

  2. Exploratory endpoint- Efficacy assessments, Overall Response Rate

    Efficacy assessments-Overall Response Rate

    Time frame: Through study completion, an average of 1 year

  3. Exploratory endpoint- Efficacy assessments, Duration of Response

    Efficacy assessments- Duration of Response

    Time frame: Through study completion, an average of 1 year

  4. Exploratory endpoint- Efficacy assessments, Progression Free Survival (PFS)

    Efficacy assessments- Progression Free Survival (PFS)

    Time frame: Through study completion, an average of 1 year

  5. Median Change from Baseline to End of Treatment in Tumor-Specific Markers, CA-125 in ovarian cancer

    Change in Tumor Specific Markers - CA-125 in ovarian cancer

    Time frame: Through study completion, an average of 1 year

  6. Median Change from Baseline to End of Treatment in Tumor-Specific Markers, PSA in Castrate Resistant Prostate Cancer

    Change in Tumor Specific Markers - PSA in Castrate Resistant Prostate Cancer

    Time frame: Through study completion, an average of 1 year

  7. Median Change from Baseline to End of Treatment in Tumor-Specific Markers, CEA in colorectal cancer

    Change in Tumor Specific Markers - CEA in colorectal cancer

    Time frame: Through study completion, an average of 1 year

07

Study locations

34 of 37 sites recruiting
  • HCG City Cancer Centre
    Vijayawada, Andhra Pradesh 520002, India
    Not yet recruiting
  • Omega Hospital
    Visakhapatnam, Andhra Pradesh 530040, India
    Recruiting
  • Post-Graduate Institute of Medical Education and Research(PGIMER)
    Chandigarh, Chandigarh 160012, India
    Recruiting
    • Dr Gaurav Prakash · Contactdrgp04@gmail.com · 9914209678
    • Dr Gaurav Prakash · Principal investigator
  • Apollo Hospital International Limited
    Ahmedabad, Gujarat 382428, India
    Recruiting
  • Universal Superspeciality Hospital
    Surat, Gujarat 395001, India
    Recruiting
  • Unique Hospital Multispeciality and Research Institute
    Surat, Gujarat 395002, India
    Recruiting
  • Kiran Hospital Multi Super Speciality Hospital & Research Centre
    Surat, Gujarat 395004, India
    Recruiting
  • Pt.B.D Sharma PGIMS Rohtak
    Rohtak, Haryana 124001, India
    Recruiting
    • Dr Sudhir Kumar Antri, MBBS · Contactssmantri74@yahoo.com · 9315895272
    • Dr Sudhir Kumar Antri, MBBS · Principal investigator
  • Sri Shankara Cancer Hospital and Research Centre
    Bangalore, Karnataka 560004, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Healthcare Global Enterprises Ltd
    Bangalore, Karnataka 560027, India
    Recruiting
  • Cytecare Hospitals Pvt. Ltd
    Bangalore, Karnataka 560064, India
    Recruiting
  • Vydehi Institute of Medical Sciences and Research Centre
    Bangalore, Karnataka 560066, India
    Recruiting
  • KLEs Dr. Prabhakar Kore Hospital & Medical Research Center
    Bangalore, Karnataka 590010, India
    Recruiting
  • K R Hospital
    Mysore, Karnataka 570001, India
    Recruiting
  • Krupamayi Hospital
    Aurangabad, Maharashtra 431001, India
    Recruiting
  • Kolhapur Cancer Centre
    Kolhāpur, Maharashtra 416234, India
    Recruiting
  • Kims-Kingsway Hospitals
    Nagpur, Maharashtra 440001, India
    Recruiting
  • Rhythm Heart And Critical Care
    Nagpur, Maharashtra 440012, India
    Recruiting
    • Dr Rahuk Darshan Arora, MBBS · Contactdrrahularora84@gmail.com · 9654438006
    • Dr Rahul Darshan Arora, MBBS · Principal investigator
  • Treat Me Hospital
    Nagpur, Maharashtra 440015, India
    Recruiting
  • Soham Hospital
    Nashik, Maharashtra 422001, India
    Recruiting
    • Dr Nilesh Wasekar, MBBS · Contactdrnilesh123@gmail.com · 9766185562
    • Dr Nilesh Wasekar, MBBS · Principal investigator
  • HCG Manavata Cancer Centre
    Nashik, Maharashtra 422002, India
    Recruiting
  • Cancure Day Care Centre
    Navi Mumbai, Maharashtra 400703, India
    Recruiting
    • Dr Shishir N Shetty · Contactdrshishir@hotmil.com · 9820102145
    • Dr Shishir N Shetty · Principal investigator
  • The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
    Navi Mumbai, Maharashtra 410210, India
    Recruiting
    • Dr Anbarasan Sekar · Contactanbarasan157@gmail.com · 022-68735000
    • Dr Anbarasan Sekar · Principal investigator
  • Grant Medical Foundation Ruby Hall Clinic
    Pune, Maharashtra 411001, India
    Recruiting
  • MMFHA Joshi Hospital
    Pune, Maharashtra 411004, India
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Novo Solitaire Care
    Pune, Maharashtra 411014, India
    Recruiting
    • Dr Mohite Aniket Balasaheb, MBBS · Contactlifelineaniket@gmail.com · 9960593303
    • Dr Mohite Aniket Balasaheb, MBBS · Principal investigator
  • Onco-Life Cancer Centre
    Pune, Maharashtra 530040, India
    Recruiting
  • Sunact Cancer Institute Pvt Ltd
    Thane, Maharashtra 400615, India
    Recruiting
  • Max Super Speciality Hospital
    New Delhi, New Delhi 110017, India
    Recruiting
  • All India Institute of Medical Sciences
    New Delhi, New Delhi 110029, India
    Recruiting
  • Sparsh Hospital & Critical care(P) LTD
    Bhubaneswar, Odisha 751007, India
    Recruiting
    • Dr Ghanashyam Biswas · Contactdrgbiswas@gmail.com · 9937500878
    • Dr Ghanashyam Biswas · Principal investigator
  • Jawaharlal Institute of postgraduate medical education and research
    Puducherry, Puducherry 605006, India
    Recruiting
    • Dr Biswajit Dubashi · Contactdrbiswajitdm@gmail.com · 8056338405
    • Dr Biswajeet Dubasi · Principal investigator
  • Apollo Cancer Hospital
    Hyderabad, Telangana 500033, India
    Recruiting
    • Dr Padmaja Lokireddy · Contactdrloki2002@yahoo.com · 9553077700
    • Dr Padmaja Lokireddy · Principal investigator
  • Basavatarakam Indo American Cancer Hospital & Research Institute
    Hyderabad, Telangana 500034, India
    Recruiting
    • Dr Pallavi Suresh Ladda · Contactjajupallavi794@gmail.com · 7207876021
    • Dr Pallavi Suresh jajupallavi794@gmail.com · Principal investigator
  • BP Poddar Hospital & Medical Research Ltd
    Kolkata, West Bengal 700053, India
    Recruiting
    • Dr Prashant Pandey · Contact2drprashant@gmail.com · 9804290687
    • Dr Prashant Pandey · Principal investigator
  • Tata Medical Center
    Kolkata, West Bengal 700160, India
    Recruiting
  • Chittaranjan National Cancer Institute
    Kolkata, West Bengal 9830115905, India
    Recruiting
    • Dr Kalyan Kusum Mukherjee · Contactkkmukherjee4u@hotmail.com · 9830115905
    • Dr Kalyan Kusum Mukherjee · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Jan 2027, 40 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 40 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2023
First posted
May 18, 2023
StartActual
Sep 5, 2023
Primary completionEst.
Jan 2027
CompletionEst.
Jun 2027
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05865002
Responsible party
Sponsor
First posted
May 18, 2023
Start date
Sep 5, 2023
Primary completion
Jan 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Apr 17, 2026

Study contacts

Suchit Kumbhare
Contact
suchit_k@aurigene.com
+91 8104730078
Suresh Oduru
Contact
suresh_o@aurigene.com
+91 9866225593
Akhil Kumar
principal investigator · Aurigene Oncology Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion